表紙:癌治療の世界市場
市場調査レポート
商品コード
912478

癌治療の世界市場

Cancer Therapies

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 915 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.93円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

癌治療の世界市場
出版日: 2021年05月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 915 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界における癌治療市場の概要、動向・発展への影響因子の分析、世界および地域・主要国別の市場規模の推移と予測、主要企業のプロファイルなどをまとめています。

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場の動向と発展因子
  • 世界市場の見通し

第3章 市場分析

  • 地域別市場の分析
    • 米国
    • カナダ
    • 日本
    • 中国
    • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • その他欧州
    • アジア太平洋地域
    • オーストラリア
    • インド
    • 韓国
    • その他アジア太平洋地域
    • ラテンアメリカ
    • アルゼンチン
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ
    • 中東
    • イラン
    • イスラエル
    • サウジアラビア
    • アラブ首長国連邦
    • その他中東
    • アフリカ

第4章 競合企業

  • AMGEN
  • ASTRAZENECA PLC
  • BAYER AG
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE AG
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER

第5章 調査資料

目次
Product Code: MCP-1551

Abstract:

Global Cancer Therapies Market to Reach US$250 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for Cancer Therapies estimated at US$155 Billion in the year 2020, is projected to reach a revised size of US$250 Billion by 2027, growing at a CAGR of 7.1% over the analysis period 2020-2027.Chemotherapy, one of the segments analyzed in the report, is projected to grow at a 7.9% CAGR to reach US$83.8 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Targeted Therapy segment is readjusted to a revised 7.3% CAGR for the next 7-year period. This segment currently accounts for a 28.9% share of the global Cancer Therapies market.

The U.S. Accounts for Over 27% of Global Market Size in 2020, While China is Forecast to Grow at a 10.9% CAGR for the Period of 2020-2027

The Cancer Therapies market in the U.S. is estimated at US$41.9 Billion in the year 2020. The country currently accounts for a 27.03% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$55.4 Billion in the year 2027 trailing a CAGR of 10.8% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.8% and 6.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR while Rest of European market (as defined in the study) will reach US$55.4 Billion by the year 2027.

Immunotherapy Segment Corners a 24.6% Share in 2020

In the global Immunotherapy segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$28.8 Billion in the year 2020 will reach a projected size of US$41.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$34.2 Billion by the year 2027, while Latin America will expand at a 7.1% CAGR through the analysis period.

Select Competitors (Total 80 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Cancer Therapies: An Outlook
    • Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
    • By Cancer Type
    • USA Leads the Cancer Therapies Market
    • Biotherapies to Drive Growth
    • Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth
    • EXHIBIT 1: Total Number of New Cancer Cases by Type: 2018
    • EXHIBIT 2: Total Number of Cancer Deaths by Type: 2018
    • EXHIBIT 3: Cancer Incidence by Region: 2018
    • EXHIBIT 4: Cancer Mortality by Region: 2018
    • EXHIBIT 5: Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018
    • Cancer Research Spending Continues to Witness Growth
    • Number of FDA-Approved Cancer Drugs: 2010-2018
    • Select Cancer Drug Approvals in 2019
    • Select Cancer Drug Approvals in 2018
    • Cancer Drug Pipeline to Change the Pharma Landscape
    • Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
  • 2. FOCUS ON SELECT PLAYERS
    • AbbVie, Inc. (USA)
    • Amgen, Inc. (USA)
    • Astellas Pharma, Inc. (Japan)
    • AstraZeneca Plc. (UK)
    • Bayer AG (Germany)
    • Bristol-Myers Squibb Company (USA)
    • Select Late Stage Compounds in Bristol-Myers Squibb Company's Oncology Pipeline (As of 2019)
    • Celgene Corporation (USA)
    • Eli Lilly and Company (USA)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Glaxosmithkline Plc (UK)
    • Johnson & Johnson Services, Inc. (USA)
    • Merck KGaA (Germany)
    • Novartis AG (Switzerland)
    • Pfizer, Inc. (USA)
    • Takeda Pharmaceutical Company Limited (Japan)
  • 3. MARKET TRENDS & DRIVERS
    • Industry Focuses on New Approaches to Treat Cancer
    • Recent Advancements in Cancer Drug Discovery
    • A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team
    • Lymphoma Therapy Developed by BeiGene Secures US FDA Approval
    • New Linker Technology for Enhancing Stability of ADCs
    • Personalized Medicine Gains Importance
    • Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care
    • EXHIBIT 6: North American Companion Diagnostics Market (2019)
    • EXHIBIT 7: European Companion Diagnostics Market by Disease Area (2019)
    • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
    • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs
    • Combination Therapy: A Double Whammy Success
    • Patent Expiries of Branded Drugs to Trigger Generic Competition
    • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
    • Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer
    • Development of Novel Drug Candidates and Potential Therapies
    • Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies
    • Rise in Patient Assistance Programs (PAPs)
    • Top Financial Concerns for Cancer Patients: Ranked In Order of Influence
    • EXHIBIT 8: Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses
    • Growth Drivers and Restraints
    • Demographics & Lifestyles Raise the Risk of Cancer
    • EXHIBIT 9: Percentage Breakdown of New Cases for All Cancers by Gender (2019)
    • EXHIBIT 10: Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019)
    • EXHIBIT 11: Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019)
    • Unmet Needs Leave Scope for Further Research and Development
    • Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
    • Increasing Investments by National Health Authorities
    • EXHIBIT 12: NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
    • Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
    • Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
    • Innovations, Improvements, and Approvals Propel Growth
    • Select Cancer Drug Approvals (2018 & 2019)
    • Emerging Challenges in Cancer Drug Development
    • Drug Failures Deter Prospects of New Therapies
    • High Prices of Targeted Therapies Act as a Speed Breaker
    • EXHIBIT 13: Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016
    • Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation
    • Limited Tumor Specificity and Toxicity
    • Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
    • Reduced Smoking
    • EXHIBIT 14: Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018
    • Reimbursement Coverage Remains a Major Challenge
    • Increase in Multidrug Resistance
    • Stringent Regulations Delay Market Approval
    • Challenges Encountered in Clinical Trials
    • Overview of Cancer Therapy Segments
    • Immunotherapy: A Promising Segment
    • EXHIBIT 15: Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019
    • Monoclonal Antibodies for Cancer Treatment
    • Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment
    • Vaccines: A Promising Future Area of Cancer Therapeutics
    • Approved Therapeutic Cancer Vaccines Worldwide
    • CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients' Immune Cells for Cancer Treatment
    • UK Researchers New Approach Holds Potential to Boost Immunotherapies
    • Targeted Therapy: An Overview
    • Types of Targeted Therapy
    • Chemotherapy: An Overview
    • Types of Chemotherapy
    • Risks Associated with Chemotherapy
    • Hormone Therapy
    • Drug Classes in Hormone Therapy
    • CANCER TYPES, APPROVED AND PIPELINE DRUGS
    • Prostate Cancer
    • EXHIBIT 16: Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018
    • Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
    • Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
    • Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)
    • Prostate Cancer Phase IV Completed Clinical Trials with Results
    • Lung Cancer
    • EXHIBIT 17: Age-Standardized Lung Cancer Rates for Select Countries
    • EXHIBIT 18: Age-Standardized Lung Cancer Rates in Men for Select Countries
    • EXHIBIT 19: Age-Standardized Lung Cancer Rates in Women for Select Countries
    • Select FDA-Approved Non-Small Cell Lung Cancer Drugs
    • Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019
    • Select Phase III Completed Clinical Trials with Results: As of December 30, 2019
    • Breast Cancer
    • Select FDA Approved Breast Cancer Drugs
    • Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
    • Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
    • Renal Cancer
    • Select FDA-Approved Renal Cell Carcinoma Drugs
    • Cervical Cancer
    • Colorectal Cancer
    • Select FDA-Approved Colorectal Cancer Drugs
    • Skin Cancer
    • Pancreatic Cancer
    • Non-Hodgkin's Lymphoma
    • Leukemia
    • Standard Approved Mode of Therapy for AML by Age Group
    • Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
    • Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
    • Bladder Cancer
    • Endometrial Cancer
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Gastrointestinal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Gynecologic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Market Overview
    • Rising Cancer Cases Spur Growth in Anti-Cancer Drugs Market
    • EXHIBIT 20: Estimated Number of New Cancer Cases and Deaths in the US (2019)
    • EXHIBIT 21: Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
    • EXHIBIT 22: Number of FDA-Approved Oncology Drugs in the US (2010-2018)
    • EXHIBIT 23: Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
    • Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent
    • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
    • A Surging US Prostate Cancer Therapeutics Market
    • Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States
    • Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care
    • CMS Hikes Reimbursement Rate for CAR-T Therapy
    • Market Analytics
    • TABLE 40: USA Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: USA 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 43: USA Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: USA 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • CANADA
    • EXHIBIT 24: Number of New Cancer Cases in Canada: 2019
    • TABLE 46: Canada Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Canada Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Canada 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 49: Canada Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Canada Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Canada 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 52: Japan Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Japan Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Japan 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 55: Japan Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Japan Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Japan 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • CHINA
    • Cancer Therapies Market: Overview
    • EXHIBIT 25: Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
    • Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products
    • TABLE 58: China Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: China Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: China 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 61: China Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: China 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • EUROPE
    • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
    • EXHIBIT 26: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
    • EXHIBIT 27: Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
    • TABLE 64: Europe Current & Future Analysis for Cancer Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 65: Europe Historic Review for Cancer Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Europe 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 67: Europe Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Europe 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 70: Europe Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Europe 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 73: France Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: France Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: France 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 76: France Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: France Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: France 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 79: Germany Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Germany Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Germany 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 82: Germany Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Germany Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Germany 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 85: Italy Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Italy Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Italy 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 88: Italy Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Italy Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Italy 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 91: UK Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: UK Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: UK 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 94: UK Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: UK Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: UK 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 97: Spain Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Spain Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Spain 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 100: Spain Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Spain Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Spain 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 103: Russia Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Russia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Russia 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 106: Russia Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Russia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Russia 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 109: Rest of Europe Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Rest of Europe Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Rest of Europe 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 112: Rest of Europe Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Rest of Europe Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Rest of Europe 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • An Insight into Asia-Pacific Market for Cancer Therapies
    • EXHIBIT 28: Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
    • TABLE 115: Asia-Pacific Current & Future Analysis for Cancer Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 116: Asia-Pacific Historic Review for Cancer Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Asia-Pacific 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 118: Asia-Pacific Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Asia-Pacific Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Asia-Pacific 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 121: Asia-Pacific Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Asia-Pacific Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Asia-Pacific 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 124: Australia Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Australia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: Australia 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 127: Australia Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Australia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Australia 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 130: India Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: India Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: India 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 133: India Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: India Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: India 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 136: South Korea Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: South Korea Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: South Korea 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 139: South Korea Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: South Korea Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: South Korea 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 142: Rest of Asia-Pacific Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Rest of Asia-Pacific Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Rest of Asia-Pacific 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 145: Rest of Asia-Pacific Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Rest of Asia-Pacific Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Rest of Asia-Pacific 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 148: Latin America Current & Future Analysis for Cancer Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 149: Latin America Historic Review for Cancer Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Latin America 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 151: Latin America Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Latin America Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Latin America 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 154: Latin America Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Latin America Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Latin America 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 157: Argentina Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Argentina Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Argentina 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 160: Argentina Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Argentina Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Argentina 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 163: Brazil Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Brazil Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Brazil 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 166: Brazil Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Brazil Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Brazil 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 169: Mexico Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Mexico Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Mexico 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 172: Mexico Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Mexico Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Mexico 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 175: Rest of Latin America Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Rest of Latin America Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Rest of Latin America 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 178: Rest of Latin America Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Rest of Latin America Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Rest of Latin America 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 181: Middle East Current & Future Analysis for Cancer Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 182: Middle East Historic Review for Cancer Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: Middle East 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 184: Middle East Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Middle East Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: Middle East 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 187: Middle East Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Middle East Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: Middle East 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 190: Iran Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Iran Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: Iran 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 193: Iran Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Iran Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: Iran 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 196: Israel Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Israel Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: Israel 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 199: Israel Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Israel Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: Israel 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 202: Saudi Arabia Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Saudi Arabia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Saudi Arabia 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 205: Saudi Arabia Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Saudi Arabia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: Saudi Arabia 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 208: UAE Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 209: UAE Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: UAE 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 211: UAE Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 212: UAE Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 213: UAE 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 214: Rest of Middle East Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Rest of Middle East Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 216: Rest of Middle East 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 217: Rest of Middle East Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Rest of Middle East Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 219: Rest of Middle East 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 220: Africa Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Africa Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 222: Africa 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 223: Africa Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Africa Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 225: Africa 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 80